GlassScriptPhysician profile
Saakshi Joshi
NPI 1407427222
$4,303.12
in general payments reported to CMS, 2019-2025
31 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $140 · 2022: $653 · 2023: $1,098 · 2024: $742 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,410.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.84 | 2023-2025 | |
| Genzyme Corporation | $519.79 | 2021-2024 | |
| Janssen Biotech, INC. | $500.72 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $192.46 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $181.27 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $179.61 | 2025 | Dupixent |
| Davol INC. | $152.75 | 2022 | |
| Gilead Sciences, INC. | $151.10 | 2025 | Livdelzi |
| Actelion Pharmaceuticals US, INC. | $150.92 | 2022-2024 | Opsumit, Uptravi |
| Emd Serono, INC. | $146.27 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $144.65 | 2022 | |
| Ardelyx, INC. | $130.20 | 2023 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.56 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $115.51 | 2021-2024 | Xarelto |
| Medtronic, INC. | $115.38 | 2024 | Signia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $82.53 | 2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $62.18 | 2022-2023 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $58.10 | 2022-2023 | |
| Qol Medical, LLC | $41.02 | 2025 | Sucraid |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.79 | 2021-2024 | Lifevest |
| Neurelis, INC. | $33.35 | 2023 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $32.57 | 2023 | Ajovy |
| Lundbeck LLC | $24.52 | 2023 | Vyepti |
| Sandoz INC. | $24.11 | 2024 | Hyrimoz |
| Lilly USA, LLC | $23.74 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $21.40 | 2024 | |
| Alexion Pharmaceuticals, INC. | $18.48 | 2024 | Ultomiris |
| Redhill Biopharma INC. | $17.62 | 2023 | |
| Celltrion USA INC. | $16.53 | 2025 | Vegzelma |
| Organon LLC | $16.45 | 2022 | |
| Neurocrine Biosciences, INC. | $14.70 | 2023 | Ingrezza, Ongentys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saakshi Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.